Loading clinical trials...
Loading clinical trials...
The purpose of this study is to measure decreases in daytime sleepiness, and disease symptoms in participants with Narcolepsy Type 2 (NT2) when taking ALKS 2680 tablets compared with placebo tablets.
Keep your clinical trial research organized — questions to ask, what to expect, and key details.
Lead Sponsor
Alkermes, Inc.
NCT07299097 · Narcolepsy Type 1, Narcolepsy Type 2
NCT06767683 · Narcolepsy Type 1, Narcolepsy Type 2, and more
NCT06952699 · Narcolepsy Type 2
NCT06251063 · Narcolepsy Type 1, Narcolepsy Type 2, and more
NCT06555783 · Narcolepsy Type 2
Alkermes Investigational Site
Boulder, Colorado
Alkermes Investigational Site
Brandon, Florida
Alkermes Investigational Site
Maimi, Florida
Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.
Start free trial →Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions